Bluebird spins itself into two companies, severing gene therapy and cancer units
Bluebird bio, once one of biotech’s flashiest companies, is taking a sweeping step as it looks to right the ship after a series of high-profile setbacks: splitting the company in two.
The Cambridge-based company will split itself into a unit focused on cancer and a unit focused on rare disease, severing the cell therapy and gene therapy units that the biotech rode to prominence. CEO Nick Leschly explained the move as a practical one, reflecting the different kinds of expertise in the disease areas.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.